Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has earned an average rating of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $14.90.

VNDA has been the subject of several research analyst reports. Wall Street Zen cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Truist Financial initiated coverage on shares of Vanda Pharmaceuticals in a research note on Thursday, March 5th. They set a “buy” rating and a $18.00 target price for the company. UBS Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. HC Wainwright raised their target price on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Finally, Zacks Research cut shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 18th.

Vanda Pharmaceuticals Price Performance

VNDA stock opened at $7.56 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.38 and a current ratio of 2.39. The company’s fifty day moving average price is $7.58 and its 200-day moving average price is $6.76. Vanda Pharmaceuticals has a one year low of $3.81 and a one year high of $9.94. The company has a market capitalization of $454.58 million, a PE ratio of -2.03 and a beta of 0.65.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). The company had revenue of $57.22 million for the quarter, compared to the consensus estimate of $59.28 million. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%. On average, equities analysts anticipate that Vanda Pharmaceuticals will post -2.18 EPS for the current fiscal year.

Insider Activity at Vanda Pharmaceuticals

In related news, SVP Timothy Williams sold 42,434 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $8.27, for a total transaction of $350,929.18. Following the completion of the transaction, the senior vice president directly owned 377,450 shares of the company’s stock, valued at approximately $3,121,511.50. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Joakim Wijkstrom sold 30,800 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $8.27, for a total transaction of $254,716.00. Following the sale, the chief marketing officer directly owned 333,469 shares in the company, valued at approximately $2,757,788.63. The trade was a 8.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 314,342 shares of company stock valued at $2,583,985 in the last ninety days. Corporate insiders own 8.90% of the company’s stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in Vanda Pharmaceuticals during the fourth quarter valued at $25,000. Russell Investments Group Ltd. raised its stake in Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,328 shares in the last quarter. Quarry LP purchased a new stake in Vanda Pharmaceuticals during the third quarter valued at $53,000. Cerity Partners LLC purchased a new stake in Vanda Pharmaceuticals during the second quarter valued at $69,000. Finally, Boothbay Fund Management LLC purchased a new stake in Vanda Pharmaceuticals during the third quarter valued at $72,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.